← Back
Data updated: Mar 10, 2026
GLENMARK SPECLT
CardiovascularDermatologyInfectious Disease
GLENMARK SPECLT is a generic drug manufacturer focused on Cardiovascular, Dermatology, Infectious Disease. Key products include ESOMEPRAZOLE MAGNESIUM.
2015
Since
23
Drugs
-
Trials
200
Approved (2yr)
Key Drugs
Recent Activity
ACYCLOVIR 2026-01-22
Labeling
NORGESTIMATE AND ETHINYL ESTRADIOL 2026-01-07
Labeling
NITROGLYCERIN 2025-12-18
LINEZOLID 2025-12-08
CLOBETASOL PROPIONATE 2025-11-20
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 33%
3 drugs
Dermatology 22%
2 drugs
Infectious Disease 22%
2 drugs
Oncology 11%
1 drugs
Gastroenterology 11%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Gastroenterology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Oncology
CASPER PHARMA LLC big-pharma
Infectious Disease, Oncology, Cardiovascular, Gastroenterology, Dermatology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Oncology, Cardiovascular
Active (17)
RYALTRIS ABIRATERONE ACETATE TERIFLUNOMIDE HAILEY 1.5/30 HAILEY FE 1.5/30 ROSUVASTATIN CALCIUM DEFERASIROX ESOMEPRAZOLE MAGNESIUM SOLIFENACIN SUCCINATE APREPITANT LINEZOLID ASPIRIN AND DIPYRIDAMOLE CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE CALCIPOTRIENE CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE ACYCLOVIR NITROGLYCERIN
Discontinued (5)
Company Info
- First Approval
- 2015-06-09
- Latest
- 2025-07-03
- Applications
- 27